Announcements Trials
Browse Landscape

Status

Completed 55Recruiting 21Unknown 12Terminated 7Active not recruiting 7Withdrawn 4Enrolling by invitation 3Not yet recruiting 2Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Conditions

Neoplasms 14Carcinoma, Non-Small-Cell Lung 8Sarcoma 6Prostatic Neoplasms 6Pancreatic Neoplasms 6Neuroblastoma 6Multiple Myeloma 6Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Ovarian Neoplasms 4Leukemia, Myeloid, Acute 4Glioblastoma 4Breast Neoplasms 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Urinary Bladder Neoplasms 2Primary Myelofibrosis 2Pheochromocytoma 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Neuroectodermal Tumors, Primitive 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × Tuberous Sclerosis × Clear all
NCT06149663 2025-01-22

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Longboard Pharmaceuticals

Available

CDKL5 deficiency disorder, Epilepsy, Epilepsies, Myoclonic, Tuberous Sclerosis, Lennox Gastaut Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡